CPT1A and cancer: CPT1A siRNA‐loaded and iRGD‐modified exosomes efficiently targets CRCs and inhibit the expression of CPT1A and its downstream gene FAO, reversing their resistance to oxaliplatin,[268] which suggests that EV‐delivered siRNAs could efficiently target drug‐resistant cancer cells and restores their therapy sensitivity.